Biotech Stocks Hit 52-Week Highs on Positive Catalysts

Earnings

โดย RTTNews·Read original

Summary · why it matters

Several biotech stocks reached 52-week highs on July 28, 2026, driven by catalysts including strong quarterly results. Incyte Corporation rose over 9% to $132.58 after reporting second-quarter revenue of $1.67 billion, a 38% increase from last year, and projecting full-year net sales of $5.13 billion to $5.26 billion. Pulse Biosciences climbed over 8% to $36.29, Shoulder Innovations surged over 15% to $24.54, Bioventus touched $13.30 with a 6% gain, and LB Pharmaceuticals reached $38.62.

Incyte Corporation ▲

Bioventus Inc ▲

Impact on stocks 5

Biotech & Genomic Medicine▲ · 2 stocks

Incyte Corporation

▲ PositiveCapitalrelevance

Reported Q2 revenue of $1.67B (+38% YoY) and raised full-year net sales guidance to $5.13B-$5.26B.

LB Pharmaceuticals Inc Common Stock

Mentioned

Health Care▲ · 2 stocks

Pulse Biosciences Inc

Mentioned

Shoulder Innovations, Inc.

Mentioned

Aging Population▲ · 1 stocks

▲ PositiveCapitalrelevance

Reached 52-week high amid sector-wide positive catalysts including strong quarterly results, but no company-specific details.